Stephen Lane

3.7k total citations · 1 hit paper
30 papers, 1.8k citations indexed

About

Stephen Lane is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Stephen Lane has authored 30 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Molecular Biology and 9 papers in Reproductive Medicine. Recurrent topics in Stephen Lane's work include Lung Cancer Research Studies (15 papers), Cancer therapeutics and mechanisms (10 papers) and Ovarian cancer diagnosis and treatment (9 papers). Stephen Lane is often cited by papers focused on Lung Cancer Research Studies (15 papers), Cancer therapeutics and mechanisms (10 papers) and Ovarian cancer diagnosis and treatment (9 papers). Stephen Lane collaborates with scholars based in United States, United Kingdom and Germany. Stephen Lane's co-authors include Scott Z. Fields, Joachim von Pawel, Graham Ross, G. Ross, J P Kleisbauer, Joan H. Schiller, Peter Clark, David J. Stewart, James Carmichael and Martin Palmer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Stephen Lane

30 papers receiving 1.7k citations

Hit Papers

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincr... 1999 2026 2008 2017 1999 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
    1999 694 citations Joachim von Pawel, Joan H. Schiller et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen Lane United States 16 1.4k 934 730 344 223 30 1.8k
G. Ross United Kingdom 18 1.4k 1.0× 309 0.3× 119 0.2× 298 0.9× 229 1.0× 48 1.8k
Constantijne H. Mom Netherlands 17 425 0.3× 397 0.4× 170 0.2× 221 0.6× 121 0.5× 57 1.1k
H Niitani Japan 17 1.4k 1.0× 862 0.9× 174 0.2× 842 2.4× 171 0.8× 61 1.8k
Maria Ornella Nicoletto Italy 18 581 0.4× 496 0.5× 121 0.2× 187 0.5× 214 1.0× 54 1.3k
Vincenzo Sforza Italy 18 680 0.5× 380 0.4× 110 0.2× 362 1.1× 79 0.4× 58 1.2k
S. J. Harland United Kingdom 18 390 0.3× 398 0.4× 134 0.2× 219 0.6× 410 1.8× 32 1.1k
K. Swenerton Canada 18 455 0.3× 367 0.4× 89 0.1× 106 0.3× 255 1.1× 31 1.1k
Ірина Давиденко United States 16 807 0.6× 403 0.4× 110 0.2× 583 1.7× 284 1.3× 33 1.6k
Maki Tanioka Japan 17 335 0.2× 261 0.3× 104 0.1× 111 0.3× 124 0.6× 76 841
Satoru Moriyama Japan 24 574 0.4× 929 1.0× 129 0.2× 486 1.4× 238 1.1× 82 1.7k

Countries citing papers authored by Stephen Lane

Since Specialization
Citations

This map shows the geographic impact of Stephen Lane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Lane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Lane more than expected).

Fields of papers citing papers by Stephen Lane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Lane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Lane. The network helps show where Stephen Lane may publish in the future.

Co-authorship network of co-authors of Stephen Lane

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Lane. A scholar is included among the top collaborators of Stephen Lane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Lane. Stephen Lane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Long, Georgina V., Jean‐Jacques Grob, Paul Nathan, et al.. (2016). Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. The Lancet Oncology. 17(12). 1743–1754. 212 indexed citations
3.
4.
Flaherty, Keith T., Michael A. Davies, Jean‐Jacques Grob, et al.. (2016). Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9502–9502. 48 indexed citations
5.
McQuade, Jennifer L., Lauren E. Haydu, Christine N. Spencer, et al.. (2016). The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib.. Journal of Clinical Oncology. 34(15_suppl). 9566–9566. 1 indexed citations
6.
Kerklaan, Bojana Milojkovic, Martijn P. Lolkema, Lot A. Devriese, et al.. (2015). Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. British Journal of Cancer. 113(5). 706–715. 19 indexed citations
7.
8.
Lin, Nancy U., Richard Greil, Mario Campone, et al.. (2011). Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. Journal of Neuro-Oncology. 105(3). 613–620. 126 indexed citations
9.
10.
11.
Ewer, Michael S., et al.. (2009). Cardiac Safety Data for Casopitant, a Neurokinin-1 Receptor Antagonist, Given with Anthracycline.. Cancer Research. 69(24_Supplement). 1118–1118. 3 indexed citations
12.
Lilenbaum, Rogério, Rudolf M. Huber, Joseph Treat, et al.. (2006). Topotecan Therapy in Patients with Relapsed Small-Cell Lung Cancer and Poor Performance Status. Clinical Lung Cancer. 8(2). 130–134. 6 indexed citations
13.
Garst, Jennifer, Richard E. Buller, Stephen Lane, & Jeffrey Crawford. (2005). Topotecan in the Treatment of Elderly Patients with Relapsed Small-Cell Lung Cancer. Clinical Lung Cancer. 7(3). 190–196. 12 indexed citations
14.
Lilenbaum, Rogério, et al.. (2004). Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Annals of Oncology. 16(1). 97–101. 30 indexed citations
15.
Treat, Joseph, Chao Huang, Stephen Lane, & Jeremey Levin. (2004). Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status. The Oncologist. 9(2). 173–181. 36 indexed citations
16.
Huinink, W. ten Bokkel, Stephen Lane, & G. Ross. (2003). Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Annals of Oncology. 15(1). 100–103. 86 indexed citations
17.
Gore, Martin, et al.. (2001). Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. British Journal of Cancer. 84(8). 1043–1046. 12 indexed citations
18.
Ross, G., Stephen Lane, & G. Dane. (2001). Long-term survival in a phase III randomised study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma. European Journal of Cancer. 37. S326–S326. 2 indexed citations
19.
Cesano, Alessandra, Stephen Lane, G. Ross, & Scott Z. Fields. (2000). Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients.. International Journal of Oncology. 17(3). 587–90. 10 indexed citations
20.
Pawel, Joachim von, Joan H. Schiller, Frances A. Shepherd, et al.. (1999). Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer. Journal of Clinical Oncology. 17(2). 658–658. 694 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Ross Breakdown of academic impact, for papers by Constantijne H. Mom Breakdown of academic impact, for papers by H Niitani Breakdown of academic impact, for papers by Maria Ornella Nicoletto Breakdown of academic impact, for papers by Vincenzo Sforza Breakdown of academic impact, for papers by S. J. Harland Breakdown of academic impact, for papers by K. Swenerton Breakdown of academic impact, for papers by Ірина Давиденко Breakdown of academic impact, for papers by Maki Tanioka Breakdown of academic impact, for papers by Satoru Moriyama
Rankless by CCL
2026